Check for updates
OPEN ACCESS
DOI: 10.46903/gjms/23.4.Suppl.2163

REVIEW ARTICLE

ANALYTICAL REVIEW ARTICLE ON NANOTECHNOLOGY IN CARDIOVASCULAR SURGERY

Abbas Jaafar Khaleel Al-Anbari[1], Ali Fadhil Obaid[2], Hayder Abdul-Amir Makki Al-Hindy[3]

[1]Department of Surgery, College of Medicine, Al-Nahrain University, Baghdad, Iraq, Departments of [2]Pediatric nursing & [3]Pharmacology and Toxicology, College of Pharmacy, University of Babylon, Hillah, Iraq

ABSTRACT

Nanotechnology and artificial intelligence (AI) are emerging as transformative forces in cardiovascular surgery, offering innovative solutions to enhance patient outcomes and surgical precision. This review analyses the potential applications, benefits, and challenges associated with integrating these technologies into cardiovascular care. Nanotechnology focuses on manipulating materials at the nanoscale to develop advanced medical applications. In cardiovascular surgery, it facilitates improved drug delivery systems that target specific tissues, thereby minimizing side effects and enhancing therapeutic efficacy. For instance, nanoparticles can deliver medications directly to atherosclerotic plaques, improving treatment outcomes for coronary artery disease. Additionally, nanosensors and imaging tools enhance early disease detection and monitoring by providing highly sensitive diagnostic capabilities. These technologies enable real-time assessments of cardiovascular conditions, thus allowing for timely interventions. AI complements nanotechnology by offering predictive analytics that can personalize treatment plans based on comprehensive patient data. AI-driven robotic surgical systems enhance procedural accuracy, reducing complications associated with traditional surgeries. Furthermore, AI improves imaging analysis through machine learning algorithms that detect subtle changes in cardiovascular structures, leading to earlier diagnoses and better management of diseases. Despite the promising advancements brought by nanotechnology and AI, several challenges persist. Regulatory hurdles can slow the integration of new technologies into clinical practice, while the need for specialized training for healthcare professionals poses another barrier. Additionally, the high costs associated with developing and implementing these advanced technologies may limit accessibility in various healthcare settings. In conclusion, the integration of nanotechnology and AI into cardiovascular surgery holds significant potential to revolutionize patient care by enhancing diagnostic accuracy and treatment efficacy. Continued interdisciplinary collaboration among researchers, clinicians, and engineers is essential to address existing challenges and fully realize the benefits of these innovative technologies in improving outcomes for patients with cardiovascular diseases. As research advances, the future of cardiovascular surgery may be marked by unprecedented precision and effectiveness driven by these cutting-edge technologies.

KEY WORDS: Artificial intelligence; Cardiovascular surgery; Heart surgery; Nanomaterial; Nanotechnology.

Cite as: Al-Anbari AJK, Obaid AF, Al-Hindy HAAM. Analytical review article on nanotechnology in cardiovascular surgery [review article]. Gomal J Med Sci 2025 Oct-Dec;23(4)Suppl:554-60. https://doi.org/1046903/gjms/23.4.Suppl.2163

1. INTRODUCTION

This article is an analytical review of the potential scope, applications, and limitations of nanotechnology in cardiovascular surgery. As cardiovascular surgery advances, it demands a diversification and evolution of materials, implants, sutures, and surgical procedures. The concepts of nanotechnology are rapidly gaining importance in cardiovascular surgery as they have the potential to address many unmet clinical needs. Nanotechnology mainly focuses on the properties and applications of materials on the nanometer scale and has high relevance to the domains of cardiovascular science and surgery.[1] Advanced materials weave together the principles of materials science and biological science, and show significant synergistic potential. Rapid progress continues to be made in the field of nanotechnology, leading to its use in various biomedical applications, and the field of nanotechnology has grown to

Corresponding Author:

Dr. Fouzia Chang
Lecturer
Department of Pediatric nursing
College of Pharmacy, University of Babylon
Hillah, Iraq.
E-mail: ali19903li@gmail.com

Date Submitted: 23-04-2025
Date Revised: 19-12-2025
Date Accepted: 02-01-2026



Figure 1: Futuristic role of nanotechnology medical technology with nanobots assisting in the cardiovascular fields

encompass numerous products and applications.[2] The aim of the work is to examine the possible role of nanotechnology in various domains of cardiovascular surgery (Figure 1).

The impact of the various possibilities of this emerging field on patient outcomes requires further analysis. The results of this work suggest a possible scope for interdisciplinary collaborations between surgeons and nanotechnologists for the solution of various aspects of problems not yet solved. The term 'nanotechnology' refers to the concept of a single molecule acting as a diagnostic agent or a therapeutic molecule.[1]

The field of nanoscience and nanotechnology covers a broad spectrum of materials and objects and focuses almost exclusively on the unique properties or uses of materials, fabrics, species, and devices that have unique 'nano' dimensions. [1, 2] Devices, materials, and structures less than 1,000 nanometers in at least one dimension are said to exhibit such characteristics. It is a marriage of the principles of materials science and biological science. The ultimate goal is to create an interplay between biological components and various devices and test the materials inside biological systems. The synergistic bond between the components of our body and altered material is used to repair and regenerate the human body. [3] The properties of nanoscale materials differ fundamentally from those at the macro and micro scales. Scientists have identified several areas where such size-dependent properties are likely to be especially useful in commercial applications. [1]

2. METHODS: LITERATURE SEARCH STRATEGY

To gather relevant literature, we searched key databases (PubMed, Scopus, Web of Science, IEEE Xplore) for articles published between 2010 and 2024. We combined terms like "nanotechnology," "cardiovascular surgery," "nanoparticles," "artificial intelligence," and "robotic surgery." We focused on peer-reviewed studies, reviews, and significant commentaries that addressed practical applications, translational challenges, or future directions of these technologies in heart and vascular surgery. Articles solely focused on non-cardiovascular areas, purely theoretical concepts, or unpublished abstracts were excluded. This search aimed to capture a broad yet focused landscape of current research and emerging trends at the intersection of these advanced fields and surgical practice.



Figure 2: PRISMA flow diagram

3. NANOTECH IN CARDIOVASCULAR SURGERY & MEDICAL TREATMENTS

The applications of nanoscale technologies in cardiovascular surgery are rapidly evolving. This section gives an overview of the vast range of applications of nanotechnology in cardiovascular surgery. As an element of Section 1, the development in each field is discussed. Sophisticated nanotechnology applications are explored in this section depending on their integration into cardiovascular surgery and practicalities. The advancement in the individual uses will be presented below in this paper.

1. Improved Drug Delivery Systems: To date, nanodrugs are often developed to improve pharmacokinetics and pharmacodynamics or specifically target their desired site of action without interfering with healthy tissue. [1] Some targeted drug delivery systems are activated by environmental factors. In cardiovascular surgery, targeted drugs minimize undesired side effects such as systemic inflammation and reduce graft occlusion by platelet inhibition; designed to target troponin proteins to assess efficacy during ischemia-reperfusion; targeted therapy is designed to increase smooth muscle thickness on the venous graft wall.[4]

2. Biosensors/Imaging: Nanosensors and imaging tools offer advances in early disease detection and monitoring. They can be targeted to the affected tissues and only require small doses of contrast or radioactive materials. [5]

3. Tissue Engineering/Regenerative Medicine: The interplay between tissue engineering and regenerative therapy is closely linked. The use of stem cells in myocardial regenerative therapy and therapeutic angiogenesis provides alternatives to donor-site morbidity by harvesting bone marrow. Tissue electric fields and scaffolds are used in tissue engineering. [5]

The role of nanotechnology is somewhat unique in manipulating small-scale key factors and for the incorporation of growth and transcription factors. [6] Gene modification of suture materials for the improvement of endothelialization is the only use of nanotechnology that has been integrated into practical use so far. [7] The increasing number of patients waiting for transplantation means the potential use of xenotypic or artificial heart valves for replacement surgery, with the aim of minimizing implantation times and the mechanical forces on the heart valve. [8] Electrical fields and/or scaffolds can be used to increase the stem cell differentiation rate in pre-operative patients with damaged heart valve implants to discourage thrombosis formation. [9, 10]

In conclusion, the potential of nanoscience to revolutionize cardiovascular surgery is substantial. The development is still very focused and principally experimental or, at best, tested in animals. There are many hurdles to surpass, including safety factors such as clearance organization and toxicological evaluations, before such philosophically guided work can be of practical surgical worth. The challenges surrounding the use of some of the technologies are breathtaking rather than merely breathtaking. The ability of nanotechnology and some natural limits to develop is accepted. It could be that the degree of government funds should now go to the development of specific tissue engineering stem and progenitor cells over encouraging the broad use of general nanotechnology tools in the hope of developing secondary gains for heart surgery.

3.1. Drug Delivery Systems

Nanotechnology offers innovative drug delivery systems for cardiovascular surgery. Nanoscale carriers of various sizes can deliver different therapeutic agents under specific conditions directly to the target area. The carriers are significantly less toxic than the drugs themselves, producing a higher therapeutic index. In addition, the system facilitates a more appropriate biological response, including elasticity, structural arrangement, ligand adhesion with the tissue, effective uptake by the desired cell, and achieving targeted site concentration. [11]

The drug solubility and stability can be improved, and remarkable drug release efficiency over a long period can be achieved. The drug release and perishable drug desolation can be controlled.[12] Nanostructures, particularly liposomes and polymeric nanoparticles, have been extensively investigated for this purpose. [1] In hyperproliferative diseases, several marketed drug formulations containing nanomedicines have been developed to avoid systemic delivery and improve treatment outcomes.[13] Some drugs containing nanomedicines have shown significant clinical results.

In the present review, the advantages, such as targeted cellular delivery and biofilm eradication, of the nanoscale delivery system in cardiovascular surgery, particularly in LVTI and PPCII, have been defined. Nanoscale carriers can store both lipophilic and hydrophilic drugs. The engineered carriers are further targeted to a specific site.[9] Attention has been clearly given to the systemic effects of the nanoscale carrier, particularly the safety profile and biocompatibility of the carrier itself. The potential augmentation to the current percutaneous coronary intervention, drug-eluting stents, and thyromimetics for LVTI is also highlighted.[14] This optimized dosing of nanomedicine would enable personalized therapeutic delivery in future directions.[15] The nanosized material is also a low-diffusing or scavenger to atherosclerotic myocardial tissue that can be generated for the design of a nanoparticle scaffold in myocardial tissue engineering. The impact of the nanoscale carrier on excipients is still under intensive investigation. Extensive further investigation is ongoing to address its future use in treating cardiovascular diseases.

3.2. Biosensors and Imaging

These technologies provide extremely important information during the implantation of cardiovascular artificial organs and devices. This diagnostic and real-time monitoring mindset is currently on the surge of a dynamic implementation process in several key application fields like electrochemical and optical label-free biosensors for cardiac troponins, oxidative stress biomarkers, ferritin, etc., from the blood, both for in vitro and in vivo implantable devices. [16] While a biochemical sensor recognizes a specific target among a complex biological environment by the use of biological molecules called receptors, a genosensor detects a nucleic acid, usually the whole DNA, but also RNA.[17]

The synergic viewpoint that emerges is one of improving common biosensors' performances, like cost, miniaturization, and high sensitivity, to transform them into nano-biosensors endowed with a type of specificity and identification capability not found in the current generation of biosensors, useful for cardiac surgery, for instance. [18]

Nanoscale biosensors have to face the paradox concerning their biocompatibility and their recognition. In the first case, this means applying an 8-nm thick ceramic layer as a protective coating, demonstrated to guarantee biocompatibility for decades. Nanostructured materials have attracted significant research interest for diagnostics and as contrast agents for image-guided therapy for the past few years.[19] The present trend is to design nanostructured materials aiming for specific targets and for dual or multimodal imaging. Nanotechnology has shown to have great potential to improve the sensitivity and resolution of various systems commonly applied to cardiovascular surgery applications, such as computed tomography, magnetic resonance imaging, and radiography.[20] A good example is image-guided surgery in which submicron contrast agents accumulate at diseased sites; they improve the resolution by visually indicating healthy from morbid tissue, improving the surgical navigation skill by more than one order of magnitude. Finally, if the chosen surgical strategy is to replace the impaired local tissue, tissue engineering can exploit nanoscale structures in the biomaterials to increase host-tissue connections.

Carbon nanostructures integrated with microelectromechanical systems technology create an implantable vascular flow sensor measuring patient-specific patterns for customized therapeutic innovation and precise monitoring. [21] Doppler-optical anisotropy-based regression informed the personalized stent fitting, saving lives following a stroke. [22] Nanomaterials are playing a crucial role in sensing a wide range of conditions, from hemodynamic parameters to blood clotting, and from thrombosis to membrane biofouling. There are paper-based sensors with a microfluidic passive valve for paper microfluidic partners, including a multianalyte sensor-based analytical platform for continuous, low-cost monitoring of cardiac biomarker panels, which can provide evidence of cardiac damage from early heart attacks or myocardial infarction. [23]

The implementation of real-time patient physiological data will create a data-driven resource to enhance medical decision-making and improve the clinical pathways for patients cared for in non-hospital settings. The device is wireless, capable of transmitting data, and does not require any external antenna. Ultra-thin, flexible encapsulating polymer material for adhering to minimally invasive patient skin portals, using surfactant-free silica nanoparticle encapsulating polymer material for wireless diagnostic functions such as electrocardiogram and respiration rates. [24]

In conclusion, nanosensors can potentially overhaul diagnostics and therapy by making precise, early, and efficient diagnosis a reality. The ability to monitor a particular kind of biomarkers could transform the whole scenario of cardiovascular diseases from complications, daunting and prolonging diagnostic tests and treatment, to curable conditions with a reduced rate of relapse.

3.3. Tissue Engineering and Regenerative Medicine

The use of nano-engineered materials is becoming more common in tissue engineering as scientists explore the regenerative capabilities of cells for repairing damaged tissue. With the aid of the appropriate molecular and cellular signals, natural stem cells can join the ongoing tissue engineering and regeneration. Of particular interest to cardiovascular surgery, nano-sized particles and fibers are used for constructing cardiac muscle bundles, vascular blood pumps, and heart valves for the repair and replacement of damaged heart tissues, while nano-engineered scaffolds are used as both a platform for cell growth and as a means of guiding tissue repair in damaged blood vessels.[9]

Nanomaterials are thought to not only improve the structural properties of scaffolds but also to be able to deliver growth factors that may stimulate stem cell differentiation towards the desired cell type. This is due largely to the strong burst of protein adsorption likely responsible for stem cell-substrate interaction enhancement.

Recent research in the field identifies a role for nanomaterials in tissue regeneration for cardiovascular disease through the delivery of bone morphogenetic proteins, which are known to initiate cardiovascular calcification in settings such as a variety of heart valve disorders. These studies suggest potential for the construction of novel "nontissue" tissue-engineering materials for more beneficial invasion therapies. [25]

However, scientists continue to grapple with our society's legal, moral, and ethical issues surrounding the widespread use of nanotechnology, but relative to drug delivery and diagnostic applications, shielding constructs used in the body may have a less restrictive regulatory pathway. Despite numerous advances, a suitable prosthetic graft to act as an artificial artery for chronic conditions, such as atherosclerosis, is still far from realization.[26]

4. CHALLENGES AND LIMITATIONS OF NANOTECHNOLOGY IN CARDIOVASCULAR SURGERY

Introducing the implementation of nanotechnology in cardiovascular surgery is not a straightforward process and comes with several challenges. This review discusses the major hurdles and limitations encountered during the use of nanotechnology in vascular and cardiac surgery. Regulatory Hurdles

Clinically, nanotechnology for utility in the cardiovascular system has just started to be investigated. Nanotechnology has the potential to bring numerous new drugs and devices into clinical practice; however, the regulatory clearance process for new therapeutic products may delay these products for several years or decades before the advent of nanotechnology in clinical practice.

Safety and Biocompatibility Target-site delivery is of particular commercial interest, and a number of companies are exploiting the use of ultrasmall particles of drugs for pharmaceutical drug delivery and are entering the clinical phase. However, there is an increasing ban on biological studies demonstrating long-term retention, sequestration, and persistence in organs such as the liver and spleen.[27]

For multifunctional nanoparticles designed for drug targeting, new aspects of toxicology issues specifically regarding new functions, new characteristics, or pharmacological activity have to be characterized entirely. For the successful translation from “bench to bed” of new products based on nanotechnology, a better understanding is needed about whether the toxicity of nanomaterials differs from their bulk counterparts.

Thus, the pharmaceutical development cycle must ensure that they are adequately characterized for toxicity and pharmacokinetics prior to product registration and commercial use. The cost and complexity of large-scale production and the production of nanoscale products are neither simple nor straightforward because the production processes must be carefully standardized and quality-controlled. The absence of suitable analytical methods is another barrier. Parameters that are difficult to measure include the size and distribution of the final products, shelf life and long-term storage stability, the optical purity of quantum dots, the specific activity in pharmaceutical applications, and the surface chemistry and reactivity for developing products.[28] Regulatory requirements for mass-producing particulate drug-delivery systems can be prohibitive.

5. FUTURE DIRECTIONS AND EMERGING TRENDS

Some of the ongoing research activities, as future directions and emerging trends, include further optimizing the techniques and equipment for the applications that are happening, including point-of-care devices. Considerations are also being made to sometimes connected areas, like real-time stress monitoring with flexible films or electronics applied directly over the heart. Furthermore, materials design methods for nanoscale design of sensors, films for repelling thrombi, ultrastrong nanosutures, polymeric microcapsules, and novel technologies to fabricate soft robotics for diagnosis and treatment are also under consideration. [27]

Artificial intelligence, especially for precise diagnostic and personalized therapeutic applications, is identifying and testing novel cutting-edge imaging and therapy techniques. Technologies not applicable yet to heart and vascular diseases are being tested.

New methods to fabricate innovative nanomaterials for cardiovascular applications are being developed, including the use of vapor materials to grow these on surfaces or to fabricate nanoparticles. Moreover, there is a trend towards a combination of nanotechnology with other cutting-edge biomedical technologies, such as gene therapy and genome editing, for permanent treatment of heritable cardiovascular diseases. [29]

Clinical experts are driving specific collaborations that have been useful to design preclinical studies and are being discussed with enterprise partners, willing to develop product prototypes that will be further optimized, feasibility studies, projects, and start-up companies in the future. In general, continuous research is important to make this vivid field of study become a reality and turn cardiovascular nanosurgeons into skilled professionals who carefully select their tools to leave a positive mark on cardiovascular surgery. In this regard, it is imperative to consider any effective, feared, and upcoming trends that show the adaptability and increase the potential of nanotechnology in cardiac and vascular surgery.

6. ARTIFICIAL INTELLIGENCE (AI) IN CARDIOVASCULAR SURGERY

Artificial Intelligence (AI) complements nanotechnology by providing advanced analytical tools that enhance surgical outcomes:

6.1. Predictive Analytics: AI algorithms analyze vast amounts of patient data to identify risk factors for CVDs and predict outcomes of surgical interventions. This capability enables personalized treatment plans tailored to individual patient profiles. [30]

6. 2. Surgical Robotics: AI-driven robotic surgical systems enhance precision during procedures by translating a surgeon’s hand movements into micro-movements of surgical instruments. This technology is particularly beneficial in delicate cardiovascular surgeries where precision is critical. [30]

6. 3. Enhanced Imaging Analysis: AI improves the interpretation of imaging data by employing machine learning algorithms that can detect subtle changes in cardiovascular structures that may be missed by human eyes. This capability leads to earlier diagnoses and more effective monitoring of disease progression.[31]

7. CONCLUSION AND IMPLICATIONS FOR CLINICAL PRACTICE

The convergence of nanotechnology and artificial intelligence is poised to redefine the paradigms of cardiovascular surgery, offering transformative potential through enhanced precision, personalized therapeutics, and intelligent diagnostic systems. While the foundational research and early-stage applications reviewed herein demonstrate considerable promise, the translation of these innovations into routine clinical practice necessitates a deliberate and collaboratively engineered strategy. It is incumbent upon the surgical, scientific, and regulatory communities to navigate the attendant challenges-ranging from biocompatibility and manufacturing scalability to ethical considerations and specialized training-with foresight and rigor.

To systematically actualize this potential, a phased roadmap is proposed, delineating clear priorities across short-, medium-, and long-term horizons:

- **Short-Term Priorities (1–3 years)** should emphasize **standardization and safety validation**. Critical initiatives must include establishing international consensus on nanomaterial characterization protocols (addressing size, surface charge, and compositional purity), executing robust toxicological and biodistribution studies under Good Laboratory Practice (GLP) standards, and initiating pilot clinical trials for the most proximate applications, such as augmented drug-eluting stents and AI-based imaging diagnostics.
- **Medium-Term Objectives (3–7 years)** must transition toward **pilot integration and scalability**. Key efforts should focus on advancing Good Manufacturing Practice (GMP)-compliant production processes to ensure reproducibility and cost-effectiveness, launching multi-center clinical trials for complex therapeutic platforms like targeted nanotherapies and hybrid AI-nanoparticle imaging systems, and developing dedicated training programs and simulation-based tools to equip clinicians with the requisite skills for these new technologies.
- **Long-Term Vision (7+ years)** aims at the **full integration of intelligent, personalized systems** into mainstream care. This will entail widespread adoption of AI-driven predictive analytics for treatment personalization, routine deployment of bioactive nanomaterial-enhanced implants capable of supporting tissue regeneration and repair, and the establishment of sophisticated ethical and regulatory frameworks to guide advanced human–AI collaboration in surgical settings.

The successful adoption of these technologies will ultimately depend on sustained interdisciplinary collaboration across academic, clinical, industrial, and regulatory domains. Such partnerships are essential to address not only technical and economic hurdles but also the societal and ethical implications inherent in these advances. By proceeding with both ambition and caution, the field can harness these innovations to significantly improve patient outcomes and redefine the future of cardiovascular care.



Figure 3: The image showcases the futuristic application of nanotechnology in cardiovascular surgery.



Figure 4: Integration of combined artificial intelligence (AI), nanotechnology in cardiovascular surgery in future medicine.

REFERENCES

1. Makki Al-Hindy HA-A, Hassnawi FSM, Obaid SR, Al-Anbari AJK. Emerging trends in nanopharmacology: new therapeutic approaches to paediatric parasitology. Pharmakeftiki. 2025;37. https://doi.org/10.60988/p.v37i2S.253
2. Kazaili A, Abdul-Amir Al-Hindy H, Madine J, Akhtar R. Nano-scale stiffness and collagen fibril deterioration: probing the cornea following enzymatic degradation using Peakforce-QNM AFM. Sensors. 2021;21(5):1629. https://doi.org/10.3390/s21051629
3. Hasan A, Morshed M, Memic A, Hassan S, Webster TJ, Marei HE. Nanoparticles in tissue engineering: applications, challenges and prospects. Int J Nanomedicine. 2018;13:5637–55. https://doi.org/10.2147/IJN.S153758
4. Boarescu I, Boarescu P-M. Drug-induced myocardial infarction: a review of pharmacological triggers and pathophysiological mechanisms. J Cardiovasc Dev Dis. 2024;11:406. https://doi.org/10.3390/jcdd11120406
5. Javaid M, Haleem A, Singh RP, Rab S, Suman R. Exploring the potential of nanosensors: a brief overview. Sensors Int. 2021;2:100130. https://doi.org/10.1016/j.sintl.2021.100130
6. Li Y, Xu C, Lei C. The delivery and activation of growth factors using nanomaterials for bone repair. Pharmaceutics. 2023;15:1017. https://doi.org/10.3390/pharmaceutics15031017
7. Zhou YL, Yang QQ, Yan YY, Zhang L, Wang QH, Ju F, et al. Gene-loaded nanoparticle-coated sutures provide effective gene delivery to enhance tendon healing. Mol Ther. 2019;27:1534–46. https://doi.org/10.1016/j.ymthe.2019.05.024
8. Hummadi Fayadh NAKA-A, Abbas J, Al-Alosi B, Maddah H. Brachial artery injury in Al-Emamain Al-Kadhymain

Medical City, Baghdad, Iraq: a single-center clinical experience. Interv Akut Kardiol. 2023;22:109. https://doi.org/10.36290/kar.2022.033

9. Razavi Z, Farokhi S, Mahmoudvand G, Karimi Rouzbahani A, Razavi ZS, Tahmasebi-Ghorabi S, et al. Stem cells and bio scaffolds for the treatment of cardiovascular diseases: new insights. Front Cell Dev Biol. 2024;12:1472103. https://doi.org/10.3389/fcell.2024.1472103
10. Ren X, Feng Y, Guo J, Wang H, Li Q, Yang J, et al. Correction: surface modification and endothelialization of biomaterials as potential scaffolds for vascular tissue engineering applications. Chem Soc Rev. 2015;44:5680–96. https://doi.org/10.1039/C4CS00483C
11. Abbasi R, Shineh G, Mobaraki M, Doughty S, Tayebi L. Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review. J Nanopart Res. 2023;25:43. https://doi.org/10.1007/s11051-023-05690-w
12. Zhuo Y, Zhao YG, Zhang Y. Enhancing drug solubility, bioavailability, and targeted therapeutic applications through magnetic nanoparticles. Molecules. 2024;29:4854. https://doi.org/10.3390/molecules29204854
13. Souto EB, de Souza ALR, Dos Santos FK, Sanchez-Lopez E, Cano A, Zielińska A, et al. Lipid nanocarriers for hyperproliferative skin diseases. Cancers (Basel). 2021;13:5619. https://doi.org/10.3390/cancers13225619
14. Manners N, Priya V, Mehata AK, Rawat M, Mohan S, Makeen HA, et al. Theranostic nanomedicines for the treatment of cardiovascular and related diseases: current strategies and future perspectives. Pharmaceuticals (Basel). 2022;15:441. https://doi.org/10.3390/ph15040441
15. Alghamdi MA, Fallica AN, Virzì N, Kesharwani P, Pittalà V, Greish K. The promise of nanotechnology in personalized medicine. J Pers Med. 2022;12:673. https://doi.org/10.3390/jpm12050673
16. Gerdan Z, Saylan Y, Denizli A. Biosensing platforms for cardiac biomarker detection. ACS Omega. 2024;9:9946–60. https://doi.org/10.1021/acsomega.3c06571
17. Ramesh M, Janani R, Deepa C, Rajeshkumar L. Nanotechnology-enabled biosensors: a review of fundamentals, design principles, materials, and applications. Biosensors (Basel). 2022;13:40. https://doi.org/10.3390/bios13010040
18. Najjar R. Clinical applications, safety profiles, and future developments of contrast agents in modern radiology: a comprehensive review. iRadiology. 2024;2:430–68. https://doi.org/10.1002/ird3.95
19. Alipour B, Alvandi V, Mehrabifard M, Talaee O, Zamani H, Tabatabayi F, et al. Advances in nano-scale metal-based contrast agents for computed tomography: a systematic review. Radiat Phys Chem. 2025;226:112195. https://doi.org/10.1016/j.radphyschem.2024.112195
20. Chircov C, Grumezescu AM. Microelectromechanical systems (MEMS) for biomedical applications. Micromachines. 2022;13:164. https://doi.org/10.3390/mi13020164
21. Ozturk C, Pak D, Rosalia L, Goswami D, Robakowski M, McKay R, et al. AI-powered multimodal modeling of personalized hemodynamics in aortic stenosis. Adv Sci. 2024;11:4755. https://doi.org/10.1002/advs.202404755
22. Hussain G, Jafry AT, Malik S, Shah SF, Nishat S, Awan FR. Multifunctional rotational active valve for flow control in paper-based microfluidic devices. Sens Actuators B Chem. 2023;378:133142. https://doi.org/10.1016/j.snb.2022.133142
23. Lin R, Lei M, Ding S, Cheng Q, Ma Z, Wang L, et al. Applications of flexible electronics related to cardiocerebral vascular system. Mater Today Bio. 2023;23:100787. https://doi.org/10.1016/j.mtbio.2023.100787
24. Farjaminejad S, Farjaminejad R, Garcia-Godoy F. Nanoparticles in bone regeneration: a narrative review of current advances and future directions in tissue engineering. J Funct Biomater. 2024;15(9):241. https://doi.org/10.3390/jfb15090241
25. Brown TK, Alharbi S, Ho KJ, Jiang B. Prosthetic vascular grafts engineered to combat calcification: progress and future directions. Biotechnol Bioeng. 2023;120(4):953–69. https://doi.org/10.1002/bit.28316
26. Zhang T, Liu N, Xu J, Liu Z, Zhou Y, Yang Y, et al. Flexible electronics for cardiovascular healthcare monitoring. Innovation. 2023;4:100485. https://doi.org/10.1016/j.xinn.2023.100485
27. Bajwa N, Mehra NK, Jain K, Jain NK. Pharmaceutical and biomedical applications of quantum dots. Artif Cells Nanomed Biotechnol. 2016;44(3):758–68. https://doi.org/10.3109/21691401.2015.1052468
28. Wu X, Yang J, Zhang J, Song Y. Gene editing therapy for cardiovascular diseases. MedComm. 2024;5:e639. https://doi.org/10.1002/mco2.639
29. Abaszadeh F, Ashoub M, Khajouie G, Amiri M. Nanotechnology development in surgical applications: recent trends and developments. Eur J Med Res. 2023;28:429. https://doi.org/10.1186/s40001-023-01429-4
30. Hu Q, Fang Z, Ge J, Li H. Nanotechnology for cardiovascular diseases. Innovation (Camb). 2022;3:100214. https://doi.org/10.1016/j.xinn.2022.100214
31. Kazaili A, Abdul-Amir Al-Hindy H, Madine J, Akhtar R. Nano-scale stiffness and collagen fibril deterioration: probing the cornea following enzymatic degradation using Peakforce-QNM AFM. Sensors (Basel). 2021;21(5):1629. https://doi.org/10.3390/s21051629

CONFLICT OF INTEREST
Authors declare no conflict of interest.
GRANT SUPPORT AND FINANCIAL DISCLOSURE
None declared.

AUTHORS' CONTRIBUTION

The following authors have made substantial contributions to the manuscript as under:

Conception or Design:	AJKA, AFO
Acquisition, Analysis or Interpretation of Data:	AJKA, AFO, HAMA
Manuscript Writing & Approval:	AJKA, AFO, HAMA

All the authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.